Introduction {#sec1_1}
============

In December 2019, several pneumonia cases in Wuhan, China were shown to be caused by a novel coronavirus causing coronavirus disease 2019 (COVID-19) \[[@B1]\]. COVID-19 typically presents as an acute respiratory illness that can quickly progress to respiratory failure. Multiorgan involvement is also common, including damage to the kidneys, heart, and gastrointestinal tract, mirroring the presence of the angiotensin-converting enzyme 2 (ACE2) receptors in these organs, which serves as a portal of entry for the virus \[[@B2]\]. In particular, acute kidney injury (AKI) as one major complication of COVID-19 occurred in 17--29% of in-hospital patients based on reports from China, the USA, and some European countries \[[@B3], [@B4], [@B5], [@B6]\]. The potential mechanisms of AKI in COVID-19 patients include direct viral cytopathic effects, cytokine damage, microthrombi in the renal circulation, and hypoperfusive injury. Furthermore, AKI was found to be a significant poor prognostic marker among patients with COVID-19 \[[@B3]\]. The described burden of AKI in patients with COVID-19 has predominantly been reported in patients of non-African American origin. There are emerging data on worse outcomes of COVID-19 in African American patients \[[@B7]\] and in patients from underserved socioeconomic groups who also have higher rates of preexisting cardiorenal metabolic disease risk factors, such as hypertension, diabetes mellitus, and obesity. These comorbidities have in turn been shown to portend an overall worse prognosis \[[@B8], [@B9], [@B10]\]. The primary objective of this study is to describe the onset, nature, characteristics, and predictive factors of AKI in this high-risk patient population with COVID-19.

Materials and Methods {#sec1_2}
=====================

This is a single-center retrospective study. We included all patients \>18 years of age who were admitted to a tertiary inner-city hospital with a confirmed diagnosis of COVID-19 via polymerase chain reaction (PCR). We excluded patients who were still hospitalized as of the time of chart review and analysis, as the final disposition related to outcomes could not be ascertained at the time of writing this report. We also excluded patients with incomplete data on clinical outcomes, those on maintenance hemodialysis, and patients on remdesivir or convalescent plasma therapy as both these were introduced in our institution protocol at the time of this data analysis. The definition used for AKI in this study was an increase in serum creatinine by at least 0.3 mg/dL or 1.5-fold from the baseline based on Kidney Disease Improving Global Outcome (KDIGO) criteria \[[@B11]\]. Patients admitted to the hospital with AKI based on the first serum creatinine measured were denoted as having community-acquired AKI (CA-AKI). In contrast, patients were identified as having hospital-acquired AKI (HA-AKI) when AKI was not apparent upon hospital admission but developed during hospitalization. The baseline serum creatinine level was defined as the lowest measured serum creatinine within the preceding 3 months. Baseline estimated glomerular filtration rate (eGFR) was computed using the CKD-API equation using the latest serum creatinine value available in that same period of time. All data were extracted from electronic medical records. Demographic variables were presented using descriptive statistics and frequencies. Categorical variables were analyzed with χ^2^ testing. Demographic and clinical variables were tabulated. The χ^2^ test was used to analyze the relationship between demographic or comorbidity variables and AKI, need for intubation, and vasopressor use. Multivariate logistic regression was used to look at the factors associated with AKI. We utilized 95% confidence intervals, which are presented when appropriate. Our study was approved by the institutional review board (IRB No. 2020-435).

Results {#sec1_3}
=======

Of the 389 patients who tested positive for COVID-19 via PCR, 122 were excluded due to being currently hospitalized, as well as 19 patients who were on dialysis and 25 patients with incomplete clinical data, leaving a final sample of 223 patients (Fig. [1](#F1){ref-type="fig"}). In that final sample, the mean age was 65.91 ± 14.95 years, 48% were female, and 68% were African American. Of the total patients (*n* = 223), 72% had hypertension, 47% had diabetes, and 49% had documented AKI. Of the patients who had AKI, 72% were diagnosed on admission (CA-AKI), while 28% developed AKI during the hospital stay (HA-AKI). There were no differences in rates of AKI based on gender (*p* = 0.52) or race (*p* = 0.50). However, there were significantly more cases of AKI among older patients (\>60 years old) compared to younger subjects (84 vs. 16%, *p* \< 0.0001). Among patients with AKI, there was a significantly higher incidence of heart failure (19 vs. 4%, *p* = 0.002), hypertension (80 vs. 64%, *p* = 0.003), and baseline chronic kidney disease regardless of stage (27 vs. 9%, *p* = 0.001). Of the patients with AKI, 8% needed continuous renal replacement therapy (CRRT) or intermittent hemodialysis (HD). Among those who required CRRT/HD, 89% were intubated and 78% died. Baseline eGFR was significantly lower among the patients who had AKI compared to those without (79.61 vs. 99.16 mL/min/1.73 m^2^, *p* = 0.002). On admission, those with AKI had higher FiO~2~ requirements (44 vs. 34%, *p* = 0.007) and D-dimer levels (5,468 vs. 2,248 ng/mL, *p* = 0.04) than those without. On urinalysis, patients who had AKI had significantly more proteinuria (74 vs. 48%, *p* = 0.003), which was predominantly subnephrotic (87%) via the urine protein to creatinine ratio, and microscopic hematuria (65 vs. 42%, *p* = 0.014). The majority (69%) of patients who had AKI had a prerenal urine electrolyte profile, while 31% had an elevated fraction excretion of sodium. This pattern did not show significant differences by age, gender, ethnicity, or human immunodeficiency virus (HIV) status. There were also no significant differences in urinary electrolyte profile between patients with CA-AKI and HA-AKI (prerenal profile in CA-AKI vs. HA-AKI = 64 vs. 81%, *p* = 0.436) as well as those intubated and non-intubated (39 vs. 31%, *p* = 0.140). The development of AKI was associated with poor clinical outcomes, including death, need for intubation, and need for vasopressors (Table [1](#T1){ref-type="table"}). Moreover, patients who had HA-AKI did worse with these clinical outcomes when compared to patients who had CA-AKI (Fig. [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}). Multivariate logistic regression found that age (OR 1.029, 95% CI 1.001--1.057, *p* = 0.042) and history of heart failure (OR 3.851, 95% CI 1.121--13.231, *p* = 0.032) were shown to be significantly associated with AKI after adjusting for baseline eGFR (Table [2](#T2){ref-type="table"}).

Discussion {#sec1_4}
==========

In this retrospective study conducted in a tertiary hospital serving predominantly African American patients as well as patients from lower socioeconomic strata, we observed that almost half of those hospitalized with confirmed COVID-19 had CA-AKI. This reported incidence of AKI among COVID-19 patients is higher compared to those reported from other regions, including China, the USA, and Europe, since December 2019 \[[@B3], [@B4], [@B5], [@B6]\].

African American patients have a low renin phenotype leading to a suppressed renin-angiotensin-aldosterone system. This theoretically confers a benefit in terms of developing acute respiratory distress syndrome, which is associated with angiotensin-1 (AT1) receptor activation \[[@B12]\]. However, given their high prevalence of comorbidities, including heart failure, chronic kidney disease, diabetes, and hypertension, they are also at very high risk of developing COVID-19-related complications, including AKI \[[@B8], [@B9], [@B10], [@B13], [@B14]\]. However, African American race was not a predictor of AKI in this analysis, which may be the result of a small sample size.

Interestingly, heart failure was consistently associated with AKI in this report, even after adjusting for baseline eGFR in the multivariate logistic regression, suggesting a possible cardiorenal component to the development of worsening kidney function. In COVID-19 patients with underlying heart failure, the development of cardiorenal syndrome (CRS) could be a type 1 CRS phenotype as a sequela of cardiomyopathy from cytokine storm/myocarditis, a type 3 CRS phenotype from the development of AKI leading to cardiac myocyte injury, or a type 5 CRS presentation with dual cardiac and kidney injury from inflammation, increased vascular permeability, and microthrombi \[[@B15], [@B16]\]. Also, heart-kidney crosstalk could be contributory to this observation, as cardiomyopathy can lead to renal congestion, hypotension, and renal hypoperfusion leading to a reduction in GFR \[[@B16]\]. In relation to this, one retrospective study reported a significant association of right ventricular dilation to mortality among COVID-19 patients \[[@B17]\]. The myocardial dysfunction can possibly be attributed to hypoxia, thrombotic events, direct viral damage, and cytokine storm in critically ill patients with severe COVID-19 \[[@B17]\]. This then can also potentially induce renal dysfunction via the cardiorenal mechanism. It is notable that in our study there was a significantly greater number of patients who needed intubation in the group with AKI compared to those without. High requirements of positive pressure ventilation in patients with COVID-19 can lead to potential deleterious hemodynamic consequences of reduced cardiac output contributing to renal hypoperfusion, which may play a role in the mechanism of AKI in these patients \[[@B18]\]. In our study, more patients who were intubated had a higher rate of having a pre-renal profile compared to those who were not intubated. However, this was not statistically significant, which is probably related to the relatively low absolute number of intubations.

This finding is also clinically relevant in the context of reported data on clinical outcomes with the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARB) in patients with COVID-19 \[[@B8], [@B19], [@B20]\]. Similarly, the premature discontinuation of ACE inhibitors or ARBs in heart failure patients in the absence of hemodynamic deterioration or severe hyperkalemia is associated with harm \[[@B21]\]. In our study, ACE/ARB use was not associated either AKI or inpatient death. Thus, it may be prudent to consider maintenance of ACEI/ARB in patients with COVID-19, particularly in those with a history of heart failure unless contraindicated by hemodynamic compromise or refractory hyperkalemia. Future controlled studies looking at the effect of the renin angiotensin aldosterone blockade on cardiovascular and kidney outcomes are necessary to better define the risk/benefit profile with these agents in patients with COVID-19.

In terms of other laboratory and clinical findings among our COVID-19 patients, a few observations were made. Patients with AKI have significantly higher D-dimer levels as well as FiO~2~ requirement on admission than those without AKI. Given these findings, it is possible that this particular group of patients had more severe COVID-19 disease on presentation. Although D-dimer has low specificity, several studies have suggested that it can be elevated in patients with AKI with activated coagulation being associated with systemic inflammatory syndrome as well in severe COVID-19 infection, along with increased interleukin-6 levels, as a consequence of cytokine release syndrome \[[@B22], [@B23]\]. Furthermore, increased FiO~2~ requirement indicative of alveolar damage and impending respiratory failure can also contribute to renal medullary hypoxia compounding the renal hypoperfusion from combined effects of endothelial damage, third-space fluid loss, and hypotension from COVID-19-induced cytokine release \[[@B16]\]. Urine sediments of these patients showed subnephrotic proteinuria and microhematuria, which are consistent with autopsy findings of kidney tissues of COVID-19 patients showing severe acute tubular necrosis with macrophage infiltration of the tubulointerstitium and diffuse proximal tubule injury with erythrocyte aggregates obstructing the peritubular capillaries \[[@B24]\]. Lastly, patients with AKI had significantly lower GFR both at baseline and during admission compared to those without AKI, which is congruous with the well-established observation that a low eGFR at baseline is considered to be a strong and consistent risk factor for AKI, especially in the critical care setting \[[@B25]\].

The findings from our study are in consonance with those from prior studies suggesting that AKI is a significant risk factor of clinical deterioration and in-hospital death among COVID-19 patients \[[@B3], [@B4], [@B6], [@B26]\]. Patients who developed HA-AKI had poorer outcomes than those with CA-AKI. Perhaps those with CA-AKI may have had easily reversible etiologies, including poor oral intake and volume depletion, while HA-AKI may signal multiorgan deterioration in the setting of severe COVID-19 or even the influence of decompensated cardiorenal mechanisms in our population. This assumption is supported by the fact that a low urine fractional excretion of sodium (FE~Na~) or urea (FE~Urea~) profile was seen in the majority of the AKI patients regardless of age, gender, ethnicity, HIV status, and onset of AKI. Arguably, low FE~Na~ can also be seen in clear-cut causes of intrinsic kidney disease, such as contrast-induced nephropathy, acute interstitial nephritis, rhabdomyolysis, and early tubular obstruction, which could be present in our patients as well \[[@B27]\]. However, based on the comparison between urine electrolytes in CA-AKI and HA-AKI, a prerenal urine index per se does not help prognosticate AKI in these patients given the lack of serial profiling and documenting any change in this pattern, especially in those with HA-AKI.

Limitations {#sec2_1}
-----------

Our study has some limitations. First, the definition of AKI did not include the urine volume-based criterion of \<0.5 mL/kg/h for 6 h \[[@B11]\], which may have led to underestimation of AKI incidence. Also, given the retrospective nature of the study, we were not able to determine if the change in kidney function at baseline was within the 48-h time period component as per the criteria of CA-AKI. Second, the effects of COVID-19 on long-term outcomes could not be assessed. The data for this study came from a single-center retrospective analysis with a predominance of African American patients with high rates of medical comorbidities; thus, the generalizability of the study findings may be limited. Third, the presence of hematuria was only ascertained using routine urinalysis by the laboratory; thus, the diagnostic significance of this finding is limited. Lastly, the majority of patients had a pre-renal urine electrolyte profile in both CA-AKI versus HA-AKI, but we were not able to determine whether patients with HA-AKI might have subsequently progressed to a different urine electrolyte profile due to the lack of serial urine electrolyte profiling.

Conclusion {#sec1_5}
==========

The burden of AKI among underserved patients with COVID-19 who are predominantly African Americans with multiple comorbidities was high. HA-AKI is associated with worse clinical outcomes compared to CA-AKI. A history of heart failure is an independent predictor of AKI with COVID-19. Other pathophysiologic mechanisms for AKI development, such as cardiorenal syndrome, have to be considered among COVID-19 patients with multiple comorbidities.
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###### 

Characteristics and outcomes of patients with COVID-19

                                        With AKI (*n* = 110)           Without AKI (*n* = 113)   *p* value           
  ------------------------------------- ------------------------------ ------------------------- ----------- ------- -------
  Age                                   70.33±12.18                    61.60±16.15               \<0.0001            
  Female gender                         50 (46)                        58 (51)                   0.422               
  Ethnicity/race                                                                                                     
   African American                     73 (66)                        78 (69)                   0.388               
   Caucasian                            6 (6)                          8 (7)                                         
   Hispanic                             11 (10)                        15 (13)                                       
   Other                                20 (18)                        12 (11)                                       
  Comorbidities                                                                                                      
   BMI                                  28.97±8.31                     30.69±9.97                0.172               
   COPD                                 12 (11)                        15 (13)                   0.683               
   Asthma                               6 (6)                          12 (11)                   0.219               
   Heart failure                        19 (17)                        5 (4)                     0.002               
   Atrial fibrillation                  15 (14)                        8 (7)                     0.126               
   Diabetes                             58 (53)                        46 (41)                   0.082               
   Coronary artery disease              20 (18)                        15 (13)                   0.360               
   Hypertension                         104 (80)                       76 (64)                   0.003               
   ACE/ARB                              39 (36)                        39 (35)                   0.889               
   CKD (any stage)                      29 (27)                        10 (9)                    0.001               
   CKD stage 1                          44 (40)                        59 (52)                   0.014               
   CKD stage 2                          38 (35)                        42 (37)                                       
   CKD stage 3A                         11 (10)                        10 (9)                                        
   CKD stage 3B                         9 (8)                          0 (0)                                         
   CKD stage 4                          8 (7)                          2 (2)                                         
  CA-AKI                                79 (32)                        N/A                                           
  HA-AKI                                History of kidney transplant   31 (28)                   3 (3)       2 (2)   0.680
  History of HIV                        4 (4)                          2 (2)                     0.442               
  Clinical and lab parameters                                                                                        
   FiO~2~% requirement on admission     44±32                          34±23                     0.007               
   Serum ferritin on admission, ng/mL   1,942±2,977                    1,385±2,065               0.201               
   D-Dimer on admission, ng/mL          5,468±7,990                    2,248±3,125               0.004               
   CRP on admission, mg/L               160±129                        120±89                    0.097               
   Procalcitonin on admission, ng/mL    2.53±6.06                      1.91±8.52                 0.645               
  Baseline eGFR                         79.61±36.86                    99.16±49.52               0.002               
  eGFR on admission                     47.73±29.91                    90.55±47.09               \<0.0001            
  Lowest eGFR in 1st week               34.99±23.70                    84.53±38.66               \<0.0001            
   Hydroxychloroquine                   67 (61)                        64 (57)                   0.587               
   Steroids                             30 (27)                        19 (17)                   0.075               
   Tocilizumab                          10 (9)                         9 (8)                     0.814               
  Clinical outcomes                                                                                                  
   Inpatient death                      34 (31)                        10 (9)                    \<0.0001            
   Need for vasopressors                35 (32)                        7 (6)                     \<0.0001            
   Need for intubation                  37 (34)                        11 (10)                   \<0.0001            

Data are presented as the mean ± SD or *n* (%). CKD, chronic kidney disease; CA-AKI, community-acquired AKI; HA-AKI, hospital-acquired AKI; N/A, not available.

###### 

Multivariate logistic regression on factors associated with AKI among patients admitted with COVID-19

                     OR      95% lower limit   95% upper limit   *p* value
  ------------------ ------- ----------------- ----------------- -----------
  Age                1.029   1.001             1.057             0.042
  BMI                1.002   0.964             1.042             0.907
  Male               ref.                                        
  Female             0.705   0.373             1.330             0.280
  African American   ref.                                        
  Caucasian          1.874   0.451             7.785             0.387
  Hispanic           0.897   0.305             2.635             0.843
  Other              1.597   0.589             4.334             0.358
  COPD               0.801   0.287             2.234             0.671
  DM                 1.435   0.747             2.754             0.278
  HTN                1.750   0.791             3.872             0.167
  HF                 3.851   10.121            13.231            0.032
  CAD                0.543   0.215             1.373             0.197
  Baseline eGFR      0.991   0.982             1.000             0.055
  ACEi/ARB use       0.663   0.335             1.313             0.239

OR, odds ratio; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HTN, hypertension; HF, heart failure; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; ACEi/ARB, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers.
